BPC-157 (Body Protection Compound 157)
BPC-157: What The Studies Actually Say
Almost everything behind BPC-157's reputation comes from rats and lab dishes, most of it from one lab. The few human reports are tiny, and no full placebo-controlled trial has ever been published. Here is what the research actually found.
Updated 22 September 2026
Before you read this
This page explains what published studies found. That is all it is. It is not medical advice, and it is not instructions for using anything. Nothing here is meant to find, treat, cure or stop any illness. The compounds discussed on this site, retatrutide included, are not approved by the FDA for use in people. Research compounds are sold for laboratory use only — not for use in humans or animals. A study tells you what happened to the people in it. It does not tell you what would happen to you. What you do with what you read here is your responsibility, so talk to a doctor first. This page is published by Ascend Vials, which sells research compounds.
Read the full guide
Confirm you have read the notice above and enter an email address. We will send you a link back to this guide, and sometimes an email when we publish a new one. You can unsubscribe any time.
You have probably heard BPC-157 called the healing peptide. Tendons, guts, joints, almost anything. Nearly every result behind that reputation comes from rats and lab dishes.
Here is what the research actually found. Every claim has a link. Read them yourself.
The 30-second version
- BPC-157 is a lab-made peptide, 15 amino acids long. It is not an approved medicine in any country.
- Almost all the evidence comes from rats and lab dishes, and most of it from one research group in Croatia.
- No full placebo-controlled human trial has ever been published. The one placebo-controlled result, in 53 people with a bowel disease, found no statistically significant difference.
- The results people quote come from tiny reports with no comparison group: 16 knee patients, 12 bladder patients, 2 volunteers.
- FDA says there is not enough human safety data to describe its risks. Nobody has studied long-term use.
- It is banned in sport. A July 2026 FDA advisory vote in its favour is only advice.
- Nothing sold online has been shown to match what the studies used. No study has checked.
What it is
BPC-157 is a lab-made chain of 15 amino acids. It is described as a piece of a bigger protein that a research group at the University of Zagreb, in Croatia, reported finding in human stomach juice. It first appeared in the scientific literature in 1993. FDA review, 2026 · Chang, 2011
In the early 2000s a Croatian drug company, Pliva, tested it as an enema for inflammatory bowel disease. Those trials were only ever reported as short meeting summaries, never as full papers. Today it is sold online as capsules, sprays and injectable vials, some labelled "research purposes only," some blended with TB-500. FDA review, 2026
Most of the research comes from one lab. In a PubMed search run on September 22, 2026, 174 of the 225 records mentioning BPC-157 listed the same author: Predrag Sikiric, of the Zagreb group. PubMed search That does not make those results wrong. It does mean whether other labs can repeat them is still an open question.
Every human study, in one table
| Study | People | Placebo group? | What it reported |
|---|---|---|---|
| Bowel disease, enema (meeting summary) | 53 | Yes | No statistically significant difference from placebo |
| Healthy volunteers, enema (meeting summaries) | 32 | Yes | No significant side effects reported. Not found in the blood |
| Knee pain, 2021 | 16 | No | 14 said their knee pain improved significantly |
| Bladder pain, 2024 | 12 | No | All 12 rated their symptoms 80% to 100% resolved |
| Into a vein, 2025 | 2 | No | No change in the blood tests they ran |
Read the size and placebo columns together. The only result with a placebo group found no clear difference. The eye-catching numbers all come from tiny studies with nobody to compare against.
The only placebo-controlled test. Fifty-three adults with ulcerative colitis were split at random between a daily BPC-157 enema and a dummy one for two weeks. Disease scores fell 3.2 points on BPC-157 and 1.6 on the dummy. That looks like double. But FDA worked out the range of likely differences, and it includes zero, meaning no difference at all. So the result was not statistically significant. It was never published as a full paper, and FDA called the data "inadequate to support the efficacy and safety" of the enema. FDA review, 2026
Knee pain. A Florida clinic looked back through a year of records and reached 16 patients by phone who had BPC-157 injected into the knee, 4 of them together with another peptide. 14 said their pain had improved significantly. Knee study, 2021 A later review reports that 7 of the 12 on BPC-157 alone said it lasted more than 6 months. Review, 2025 The fine print: nobody got a dummy injection, and people rated their own pain over the phone, mostly 6 months to a year later. No specific tools were used to measure function or daily activities. Knee study, 2021 · FDA review, 2026
Bladder pain. The paper calls itself a pilot study, but its full text describes a look back at the records of 12 women at one Florida clinic, all with bladder pain a standard drug had not helped. Each had BPC-157 injected into the bladder wall during a single procedure. 10 rated their symptoms 100% resolved and 2 rated them 80%. No side effects were reported. The fine print: no comparison group, the scores are the women's own ratings, and most were asked 4 to 6 months after treatment, so it is not clear when the scores were collected. Bladder study, 2024 · Full text
Into a vein. Two people who had had BPC-157 before got it through a drip on two days. Their heart, liver, kidney, thyroid and blood sugar tests did not change, and no side effects were reported. Vein study, 2025 Two people followed for three days cannot show that something is safe.
Still waiting. A 2015 tablet trial and a company-run 2025 gummy study never posted results. Tablet trial · Gummy study A proper placebo-controlled test is under way in China: 120 people with hamstring strains, split at random between BPC-157 and a dummy. Its main data collection is due to finish around February 2027. Trial record
There is no human BPC-157 number a chart would show honestly. The one placebo-controlled result was not statistically significant, and the results people quote had no comparison group. So there is no chart here.
What the animal studies found
A rat result tells scientists what to test next in people. It does not tell you what happens in a person.
Tendons. Rats had an Achilles tendon cut. Over two weeks, the BPC-157 tendons took more force to break and the rats walked better than rats given salt water. Staresinic, 2003
Gut. Rats had a hole made between the colon and the skin. From day 3, the holes in BPC-157 rats were about 40% smaller than in untreated rats, and by day 28 they looked closed to the eye. FDA notes there was no microscope data, and a much bigger dose worked no better than a small one. FDA review, 2026 · Klicek, 2008
Stomach. In rats given high doses of painkillers like aspirin, the stomach and gut damage looked more than 75% smaller with BPC-157. It was judged by eye only. FDA review, 2026
Bone, muscle and spine. Rabbits with a gap cut in a forearm bone healed about as well on BPC-157 as with a bone graft. Sebecic, 1999 Rats healed with stronger muscle after a thigh muscle was cut through, and moved their tails better after a spinal cord injury. Staresinic, 2006 · Perovic, 2019
The fine print: the tendon, stomach, bone and spinal cord studies all came from the Zagreb group. And FDA says the rat gut and liver studies never showed that more BPC-157 gives a bigger effect, the pattern scientists look for as a sign the drug is doing the work. FDA review, 2026
How it is supposed to work
Nobody knows yet. FDA says its molecular targets "have not been identified." FDA review, 2026 The ideas come from cells and animals. None has been confirmed in a person.
- New blood vessels. In human blood-vessel cells in a dish, BPC-157 boosted a receptor called VEGFR2 and switched on the signals behind it. Rats with blocked leg blood flow got it back faster. Hsieh, 2017 A 2026 cell study reports it binds a protein called FBXO22, which may be how it does this. Zhang, 2026
- Tendon cells. It did not make rat tendon cells multiply, but it helped them move and survive stress. Chang, 2011 It also raised their growth hormone receptors up to sevenfold in 3 days. Chang, 2014
It disappears fast, at least in animals. Given into a vein, half of it was gone in about 15 minutes in rats and 5 in dogs. After 4 hours the intact peptide could not be found. The body chops it into small pieces. He, 2022 In people, nobody knows: FDA found no human data for the mouth, under the skin or the nose, and after enemas it was not found in the blood at all. FDA review, 2026
Side effects: very little has been counted
FDA's 2026 review concluded there is "insufficient clinical safety information to characterize the safety profile" of BPC-157. The longest human use it found was daily enemas for two weeks. FDA review, 2026
The small human studies reported no side effects. FDA notes they were small and short, and mostly did not make clear how safety was checked. In the healthy-volunteer enema study, headache and gas were most common, at about the same rate as placebo. FDA review, 2026
FDA's side-effect reports had 3 cases through December 2025, all injected: redness and swelling for 9 days where a woman injected (she was also injecting compounded thymosin), shortness of breath that sent a man to the emergency room, and a woman whose skin and gums turned dark after a week on a "research purposes only" BPC-157 and TB-500 blend. It came back when she restarted and stopped when she quit. FDA says the blend makes BPC-157's part impossible to judge. FDA review, 2026
Animal safety tests. In 28-day injection studies, a blood-clotting test shifted in male rats and dogs, and female rats had a higher liver enzyme and blood sugar two weeks after stopping. FDA called these "clinically relevant safety signals." FDA review, 2026 The same tests found no gene damage and no malformed babies in pregnant rats, and the authors called it "well tolerated." Xu, 2020
The immune worry. FDA says injected or nasal BPC-157 "may pose a significant risk for immunogenicity," the immune system treating it as an invader. No study has formally checked. FDA review, 2026
The cancer question. Its best-documented lab effect is growing new blood vessels, and tumors use new blood vessels too. A 2025 review lists that among its possible side effects, while also citing lab reports of it slowing melanoma cells. Review, 2025 FDA found no cancer study. FDA review, 2026 So this is an open question, not a finding either way.
Is it approved?
No. FDA's 2026 review found no approved product containing BPC-157 in any country. FDA review, 2026
You may have read that FDA approved or legalized it in 2026. It did not. In order:
- FDA used to list it among compounding ingredients that "may present significant safety risks." It is now listed as "nominated but withdrawn," because the people who nominated it withdrew, and FDA's safety concerns are still on that page. That did not put it on any allowed list. FDA list · FDA nominations
- In May 2026, FDA's own staff recommended not adding it to the list of ingredients pharmacies may use. FDA review, 2026
- On July 23, 2026, an outside advisory committee voted 8 to 6, with 1 abstaining, in favour of adding it. ABC News
- The vote is only advice. FDA makes that change through a formal rule with public comment, and as of September 22, 2026, no proposed rule had been published. FDA · Federal Register The US Anti-Doping Agency's page, updated in August 2026, says "there is no legal basis to include BPC-157 in any compounded medication." USADA
Australia made it prescription-only on June 1, 2024, and having it without legal authority is illegal. Poisons Standard, 2024 New Zealand's medicines committee recommended making it prescription-only in 2023. Medsafe, 2023 Sport: the World Anti-Doping Agency has banned it at all times since 2022, and labs have a urine test for it. WADA · USADA, 2022 · Cox, 2017
What is still unknown
- Whether it works in people, for anything.
- How much reaches the blood in a person, by any route.
- Long-term safety. No published human study went past two weeks.
- Cancer risk, and whether the body makes antibodies against it.
- Whether the Zagreb results hold up when other labs repeat them.
- Whether BPC-157 and TB-500 blends do anything, or are safe. No trial has tested them.
What is in the bottle is not what was studied
One more thing.
Almost every BPC-157 result on this page came from a lab experiment. Rats. Rabbits. Cells in a dish. The enema trials used a drug company's own material. The knee and bladder reports used BPC-157 from US compounding pharmacies. FDA review, 2026 · Bladder full text
FDA judged BPC-157 not well characterized, pointing to missing data on impurities, clumping and bacterial toxins. FDA review, 2026
No study has ever shown that a product sold online as "BPC-157" is the same thing the studies used. Not the same purity. Not the same strength. Not even proof it is the same molecule.
So take every number on this page for what it is. It describes the material each study used, mostly in rats. It describes nothing else.
How to check a number yourself
You are going to see more claims about BPC-157. In a reel. In a comment. On somebody's store page.
Here is how to tell a real one from a marketing one. Five questions. About ten seconds each.
1. Is there a link to a study?
No link means it is a claim, not a result. Search the name on pubmed.gov yourself. A meeting summary is not a full paper either. The only placebo-controlled BPC-157 trial never got past that stage.
2. Was it done in people?
For BPC-157, usually not. Look for "rats", "rabbits" or "cells" near the top. A rat result is a reason to run a human study. It is not a human result.
3. Was there a group that got nothing?
That group is the whole point. In the bowel-disease trial, scores fell on the dummy enema too. Without that group, nobody can tell how much of a change was BPC-157.
4. How many people, and who measured?
Small studies swing. "14 of 16 felt better" means less when patients rated themselves over the phone, months later.
5. Has anyone else repeated it?
Most BPC-157 research comes from one lab. That does not make it false. It means nobody independent has checked.
Now run those five on this page
Every number above links to its paper and says whether it came from people, rats, rabbits or dishes. The human study sizes and placebo groups are in the table.
Whatever a seller claims BPC-157 does in people, there is no full placebo-controlled human study to link to, because none has been published.
That is the whole difference: a number you can check, and a number you are asked to believe.
This page has a date on it, near the top. When the hamstring trial reports, this page changes.
Read the studies yourself
- FDA review of BPC-157, 2026 — the main one
- In people: knee pain · bladder pain (full text) · into a vein · 2025 review · tablet trial · gummy study · hamstring trial
- Animals and dishes: Staresinic 2003 · Staresinic 2006 · Klicek 2008 · Sebecic 1999 · Perovic 2019 · Chang 2011 · Chang 2014 · Hsieh 2017 · Zhang 2026 · He 2022 · Xu 2020 · 2025 risk review
- Who does the research: PubMed author search
- Rules: FDA safety-risk list · FDA nominations · FDA rulemaking · ABC News · Federal Register · Poisons Standard · Medsafe · WADA · USADA · USADA 2022 · Cox 2017
Almost everything above about BPC-157 describes lab and animal experiments. The few human reports were small, and most had no comparison group. This is not advice, a plan, or instructions. BPC-157 is not an approved medicine. Research compounds are not for human or animal use.